The reimbursement applications that companies of SGLT-2 inhibitors filed to receive reimbursement for their heart failure indication are expected to undergo a difficult journey. The largest barrier to their reimbursement is the concern over the enormous amount of fiscal spending the drugs will bring due to the broad target patient group.

According to industry sources on the 4th, the representative SGLT-2 inhibitors ‘Forxiga (dapagliflozin)’ and ‘Jardiance (empagliflozin)’ are working to extend their reimbursement from diabetes to heart failure. Forxiga has applied for the reimbursement of its heart failure reduced ejection fraction treatment indication and plans to apply for reimbursement of